TRIALBEE
Trialbee , the leading enrollment performance company, and Castor , a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.
Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs.
“We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment channels,” said Derk Arts, M.D., Ph.D., CEO & Founder, Castor. “Our partnership provides sponsors a seamless decentralized and hybrid clinical trial solution to manage all their clinical trial touchpoints and expand inclusivity at a global scale.”
Recruiting and retaining qualified clinical trial participants is increasingly difficult as clinical study designs become more complex. According to industry estimates, the amount of patient eligibility in clinical trials has increased approximately 150% in the last decade. As a result, life sciences companies demand a patient matching and enrollment platform that can help them better manage the patient’s journey into a clinical trial while optimizing enrollment outcomes. With Trialbee and Castor’s proven integrations, clinical trial sponsors can seamlessly manage all clinical trial touchpoints while ensuring data quality every step of the way.
“Over 70 percent of potential clinical trial participants live more than two hours away from a trial site, increasing the need for greater scale and reach in patient awareness for today’s trial designs,” said Matt Walz, Chief Executive Officer at Trialbee. “Through our combined capabilities, clinical trials can deploy an end-to-end solution to simplify the patient journey, including early introductions to clinical trials, enrollment performance analytics, and remote data capture for decentralized clinical trials.”
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our enrollment platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs, and virtual/decentralized sites, and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com .
About Castor
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005078/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
BoConcept, Lego, Lurpak, and Pandora are among the Honoured Winners of the 2025-2026 World Branding Awards in Osaka17.11.2025 11:48:00 CET | Press release
The 20th World Branding Awards celebrated the success and achievements of leading brands across National, Regional, and Global categories. In the 2025–2026 edition, over 1,092 brands from 66 countries were nominated as “Brand of the Year”. From this distinguished selection, fewer than 100 brands emerged as winners, representing the highest standards of excellence across the three tiers of recognition. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. Over 80 international guests joined the celebration, hosted by Allie Sakakibara and enriched by a keynote from Miho Noguchi on immersive brand experiences. Honoured as Global winners in branding across diverse industries were Cadbury (USA), IKEA (Sweden), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). Winners from Denmark include BoConcept, Lego, Lurpak, and Pandora.Other National tier winners incl
Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 11:43:00 CET | Press release
Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 11:30:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 11:15:00 CET | Press release
EV drivers of any car brand using the EV Driver by WEX app can now charge at one of Europe’s largest and most reliable charging networks, benefitting from low-cost fast charging across 1,500+ locations. WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: compari
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom